Benjamin Heyman is a Hematology physician affiliated with UC San Diego Health System. OpenAlex indexes 54 publications with 792 citations (h-index 12); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1000 Fivepoint Ste 1000a
Irvine, CA 926182377
Telephone
949-671-4673Provider last certified this registry record 16 Jun 2025.
Clinical trials
- Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor: City of Hope Medical Center
- Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
Sponsor: University of California, San Diego
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SOBI, INCProgram year20251 payment
- Regeneron Pharmaceuticals, Inc.Program year20252 payments
- Cardinal Health 110 LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
28%Kinase inhibitor11.6%Brukinsa37%Calquence31%Imatinib Mesylate16%Jakafi16%Part D<11 patientsThalidomide Analog9%Revlimid85%Lenalidomide15%Part D<11 patients+ 3 more classes in this area
Dermatology
20.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor20.1%Acyclovir100%Part D≥46 patientsMetabolism & gastrointestinal
18.7%Corticosteroid5.3%Prednisone100%Part D≥16 patientsSerotonin-3 Receptor Antagonist5.1%Ondansetron Hcl65%Ondansetron Odt35%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Antibody Therapy for Patients with Lymphoid Malignancies: Past and Present
International Journal of Molecular Sciences
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Andrew Lowy, MD
UC San Diego Health System
Roger Spragg, MD
UC San Diego Health System
Rafael Bejar, MD, PhD
UC San Diego Health System
Zea Borok, MD
UC San Diego Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”